Kazi, M.A.I.; Kamal, H.; Mufarrih, S.M.; Qureshi, I.; Singh, S.; Mazer, A.
Glucagon-like Peptide-1 Receptor Agonist Therapy and Risk of Pulmonary and Systemic Infections in Diabetic Gastroparesis: A Propensity-Matched Cohort Study. Adv. Respir. Med. 2026, 94, 20.
https://doi.org/10.3390/arm94020020
AMA Style
Kazi MAI, Kamal H, Mufarrih SM, Qureshi I, Singh S, Mazer A.
Glucagon-like Peptide-1 Receptor Agonist Therapy and Risk of Pulmonary and Systemic Infections in Diabetic Gastroparesis: A Propensity-Matched Cohort Study. Advances in Respiratory Medicine. 2026; 94(2):20.
https://doi.org/10.3390/arm94020020
Chicago/Turabian Style
Kazi, Muhammad Ali Ibrahim, Hasan Kamal, Syed Musa Mufarrih, Imran Qureshi, Sanmeet Singh, and Adrien Mazer.
2026. "Glucagon-like Peptide-1 Receptor Agonist Therapy and Risk of Pulmonary and Systemic Infections in Diabetic Gastroparesis: A Propensity-Matched Cohort Study" Advances in Respiratory Medicine 94, no. 2: 20.
https://doi.org/10.3390/arm94020020
APA Style
Kazi, M. A. I., Kamal, H., Mufarrih, S. M., Qureshi, I., Singh, S., & Mazer, A.
(2026). Glucagon-like Peptide-1 Receptor Agonist Therapy and Risk of Pulmonary and Systemic Infections in Diabetic Gastroparesis: A Propensity-Matched Cohort Study. Advances in Respiratory Medicine, 94(2), 20.
https://doi.org/10.3390/arm94020020